Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect

NCT02876640 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02876640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02876640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Terminated
Start date
March 16, 2018
Completion date
June 3, 2022
Enrollment
27 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage i breast cancer ajcc v8, anatomic stage ia breast cancer ajcc v8, anatomic stage ib breast cancer ajcc v8, anatomic stage ii breast cancer ajcc v8, anatomic stage iia breast cancer ajcc v8, anatomic stage iib breast cancer ajcc v8, breast ductal carcinoma in situ, early stage breast carcinoma, invasive breast carcinoma